Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Head and Neck Neoplasms 174Squamous Cell Carcinoma of Head and Neck 147Nasopharyngeal Carcinoma 126Oropharyngeal Neoplasms 25Thyroid Neoplasms 23Nasopharyngeal Neoplasms 21Mouth Neoplasms 21Carcinoma, Squamous Cell 19Laryngeal Neoplasms 17Neoplasms 15Radiation Injuries 13Hypopharyngeal Neoplasms 13Salivary Gland Neoplasms 11Carcinoma 11Stomatitis 10Recurrence 10Laryngeal Diseases 10Tongue Neoplasms 9Mucositis 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Pain 7Neoplasm Metastasis 7Esthesioneuroblastoma, Olfactory 7Xerostomia 6Uterine Cervical Neoplasms 6Differentiated Thyroid Cancer 6Breast Neoplasms 6Thyroid Cancer, Papillary 5Parathyroid Neoplasms 4Melanoma 4

Interventions

trametinib 1lenvatinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Differentiated Thyroid Cancer (DTC) × Head & Neck × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

NCT02966093 2022-01-26

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Eisai Inc.

Phase 3 Completed
151 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡